Alkeon Capital Trims Stake in BioCryst Pharmaceuticals

Biotechnology firm sees institutional investor reduce position by 4.4%

Mar. 15, 2026 at 7:23am

Got story updates? Submit your updates here. ›

Alkeon Capital Management LLC, a major institutional investor, has decreased its stake in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) by 4.4% during the third quarter. The firm now owns approximately 2.60% of the biotechnology company's shares, down from a previous holding of 5,464,021 shares.

Why it matters

BioCryst Pharmaceuticals is a clinical-stage biotechnology company focused on developing novel oral medicines for rare and serious diseases. The reduction in Alkeon Capital's position could signal a shift in investor sentiment around the company's prospects, though it remains a significant shareholder.

The details

According to a recent SEC filing, Alkeon Capital sold 250,000 shares of BioCryst Pharmaceuticals during the third quarter, reducing its total position to 5,464,021 shares. The firm now owns approximately 2.60% of the company's outstanding stock, down from 2.72% previously. BioCryst Pharmaceuticals is a Durham, North Carolina-based biotech focused on leveraging structure-based drug design to advance a pipeline of targeted therapeutics.

  • Alkeon Capital reduced its position in BioCryst Pharmaceuticals during the third quarter of 2026.

The players

Alkeon Capital Management LLC

A major institutional investor that has decreased its stake in BioCryst Pharmaceuticals.

BioCryst Pharmaceuticals, Inc.

A clinical-stage biotechnology company headquartered in Durham, North Carolina that focuses on developing novel oral medicines for rare and serious diseases.

Got photos? Submit your photos here. ›

The takeaway

The reduction in Alkeon Capital's position in BioCryst Pharmaceuticals could signal a shift in investor sentiment around the company's prospects, though the firm remains a significant shareholder in the clinical-stage biotech firm.